Optimization of the aromatase inhibitory activities of pyridylthiazole analogues of resveratrol
摘要:
Aromatase is an established target not only for breast cancer chemotherapy, but also for breast cancer chemoprevention. The moderate and non-selective aromatase inhibitory activity of resveratrol (1) was improved about 100-fold by replacement of the ethylenic bridge with a thiadiazole and the phenyl rings with pyridines (e.g., compound 3). The aromatase inhibitory activity was enhanced over 6000-fold by using a 1,3-thiazole as the central ring and modifying the substituents on the 'A' ring to target the Met374 residue of aromatase. On the other hand, targeting the hydroxyl group of Thr310 by a hydrogen-bond acceptor on the 'B' ring did not improve the aromatase inhibitory activity. (C) 2012 Elsevier Ltd. All rights reserved.
用于心力衰竭的一类新型治疗药物,高效和选择性的GRK2抑制剂,在体外研究中表现出增强的β-肾上腺素信号传导能力。HTS将衍生物5和1,2,4-三唑衍生物24a鉴定为命中化合物。新一代的脚手架和所有部分的SAR研究都产生了带有N-苄基羧酰胺部分的4-甲基-1,2,4-三唑衍生物,对GRK2的活性很高,对其他激酶的选择性更高。在亚型选择性方面,这些化合物对GRK1、5、6和7表现出足够的选择性,并且对GRK3具有几乎相同的抑制作用。我们的药物化学努力导致发现了115h(GRK2 IC 50= 18 nM),获得了与人GRK2和GRK2抑制剂的共晶体结构,该抑制剂增强了β-肾上腺素能受体(βAR)介导的cAMP积累,并防止了用异丙肾上腺素处理过的表达β2AR的HEK293细胞中βAR的内在化。因此,115h似乎是心力衰竭治疗的一种新型疗法。